The Life Sciences and Public M&A teams advised Esperion Therapeutics (“Esperion”) on entering into a definitive agreement with ARCHIMED, a leading investment firm focused exclusively on healthcare industries, under which funds managed by ARCHIMED will acquire Esperion in a transaction valued at up to approximately $1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones. Under the terms of the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100 million in the aggregate tied to future net sales performance. The upfront cash consideration represents a premium of 58% to Esperion’s closing share price on April 30, 2026.
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease. With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.
The Goodwin team was led by Lisa Haddad, Jean Lee, Stuart Cable, Andrew Yu, Kaitlyn Buffaloe, Madeline Linder, Christopher Li, Michael Shuster, Duncan Greenhalgh, Noelle Dubiansky, Miho Kaneko, Gina Kim, Alex Denniston, James Devendorf, James Oh, Jennifer Fay, Lauren NuDelman, Julie Tibbets, Krupa Zachariah, Jackie Klosek, Curtis McCluskey, Jacob Lee, Arman Oruc, Ortal Ben-Aharon, Arom Yun, Heath Ingram, Nathan Brodeur, Dan Karelitz, Shlomo Gottesman, Kristopher Ring, Arthur Nahas, Liza Craig, Candi Alfred, Brian Mukherjee, Jacob Osborn, Gozde Guckaya, Carrie Clowney, James Barri, Mitchell Bloom, Justin Platt, Karin Yoo, Andrea Akinbola, and Angela Kim.
For more information on the deal, please read the press release.